The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy

This publication has 62 references indexed in Scilit:

• Potential alternatives to COX 2 inhibitors
  BMJ, 2002
• Cyclooxygenase-2—10 Years Later
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Dual acting anti-inflammatory drugs: a reappraisal
  Pharmacological Research, 2001
• Role of cyclooxygenase-2 in gastric mucosal defense
  Life Sciences, 2001
• Neutrophils, Endothelial Cells, and Cysteinyl Leukotrienes: A New Approach to Neutrophil-Dependent Inflammation?
  Biochemical and Biophysical Research Communications, 2001
• Discovery and development of ML3000
  Inflammopharmacology, 2001
• The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase
  Inflammopharmacology, 2001
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient Mice
  Published by Elsevier ,1997
• Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
  New England Journal of Medicine, 1984